title: [Efficiency of medical versus endovascular treatment using drug-eluting stents in coronary heart disease patients with extensive lesion of the coronary bed].
abstract: The goal of the study was to assess the long-term results of endovascular treatment using drug-eluting stents in coronary heart disease patients with extensive coronary artery lesion. The study covered 478 patients with diffuse coronary artery lesion, including 220 patients receiving endovascular treatment and 258 having medical treatment (a comparison group). The immediate angiographic results and long-term clinical efficiency of endovascular treatment using rapamycin-eluting stents were studied. The follow-up was 2 years. Repeat follow-ups were undertaken1and 2 years later. The immediate angiographic success rate of endovascular treatment for diffuse coronary artery lesions was 89.5%. The two-year follow-up showed the efficiency and expediency of endovascular treatment for extensive coronary artery lesions: the symptoms of angina pectoris occurred significantly less frequently symptoms, the exercise endurance was higher, and the need for antianginal medications was less in the invasively treated patients.
authors.forename: K A
authors.initials: KA
authors.lastname: Savost'ianov
authors.forename: O V
authors.initials: OV
authors.lastname: Cherkavskaia
authors.forename: A P
authors.initials: AP
authors.lastname: Savchenko
authors.forename: B A
authors.initials: BA
authors.lastname: Rudenko
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D017023:Coronary Angiography / Q000379:methods*; D054059:Coronary Occlusion / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000175:diagnosis; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D012720:Severity of Illness Index; D020123:Sirolimus / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D007166:Immunosuppressive Agents; D020123:Sirolimus